Senores Pharma Reports Strong FY26 Growth, Acquisition Boosts Results

Senores Pharmaceuticals Ltd has announced robust financial results for the fiscal year ended March 31, 2026, with its consolidated net profit more than doubling. The company reported a significant jump in annual revenue alongside completing a strategic acquisition.

For the full fiscal year (FY26), Senores Pharma's consolidated net profit surged by 108.31% to ₹121.53 Crores. This strong profitability was driven by a 62.77% increase in consolidated total income, which reached ₹679.59 Crores.

In the fourth quarter (Q4 FY26), the company posted a consolidated net profit of ₹36.67 Crores. Consolidated total income for the quarter grew by 45.15% year-on-year to ₹182.86 Crores.

The company also highlighted the successful acquisition of a 75% stake in Apnar Pharma Private Limited during Q4 FY26. This strategic move is expected to expand Senores Pharma's market reach and product portfolio.

Despite the strong growth and acquisition, investors will be watching two key areas closely. Firstly, consolidated trade receivables have seen a substantial increase, jumping 162% from ₹123.69 Crores in FY25 to ₹324.82 Crores in FY26. This surge requires careful management to ensure revenue quality and healthy cash flow.

Secondly, the company noted the resignation of its Company Secretary and Compliance Officer, effective June 10, 2026. Investors will monitor any potential governance implications arising from this management change.

Senores Pharmaceuticals is an Indian pharmaceutical firm involved in manufacturing and marketing formulations and active pharmaceutical ingredients (APIs). While currently smaller in scale compared to peers like Ajanta Pharma Ltd and Laurus Labs Ltd, its recent performance and acquisition signal potential for future expansion. Investors will now focus on the company's ability to manage its increased receivables and integrate the new acquisition effectively.